McKesson (MCK) Scheduled to Post Earnings on Thursday

McKesson (NYSE:MCK) is set to post its quarterly earnings results after the market closes on Thursday, May 6th. Analysts expect McKesson to post earnings of $5.00 per share for the quarter. Individual that wish to register for the company’s earnings conference call can do so using this link.

McKesson (NYSE:MCK) last released its quarterly earnings results on Monday, February 1st. The company reported $4.60 EPS for the quarter, topping the consensus estimate of $4.13 by $0.47. The company had revenue of $62.60 billion for the quarter, compared to analyst estimates of $61.70 billion. McKesson had a return on equity of 45.52% and a net margin of 0.95%. The firm’s revenue was up 5.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $3.81 earnings per share. On average, analysts expect McKesson to post $16 EPS for the current fiscal year and $17 EPS for the next fiscal year.

NYSE:MCK opened at $192.12 on Tuesday. The firm has a market cap of $30.58 billion, a P/E ratio of 14.62, a PEG ratio of 1.70 and a beta of 0.94. The company has a current ratio of 0.99, a quick ratio of 0.56 and a debt-to-equity ratio of 0.96. The stock’s 50 day simple moving average is $191.70 and its 200-day simple moving average is $179.04. McKesson has a 12-month low of $125.65 and a 12-month high of $198.43.

The business also recently announced a quarterly dividend, which will be paid on Thursday, July 1st. Stockholders of record on Tuesday, June 1st will be issued a $0.42 dividend. This represents a $1.68 dividend on an annualized basis and a dividend yield of 0.87%. The ex-dividend date of this dividend is Monday, May 31st. McKesson’s payout ratio is currently 11.24%.

McKesson declared that its board has initiated a share buyback plan on Tuesday, February 2nd that authorizes the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization authorizes the company to reacquire up to 6.9% of its shares through open market purchases. Shares repurchase plans are typically an indication that the company’s management believes its stock is undervalued.

A number of research analysts have recently issued reports on the company. Cowen boosted their target price on McKesson from $210.00 to $224.00 and gave the company an “outperform” rating in a report on Tuesday, March 2nd. Morgan Stanley boosted their target price on McKesson from $219.00 to $226.00 and gave the company an “overweight” rating in a report on Wednesday, February 3rd. Deutsche Bank Aktiengesellschaft upped their price objective on McKesson from $222.00 to $231.00 and gave the stock a “buy” rating in a report on Wednesday, February 3rd. Argus raised McKesson from a “hold” rating to a “buy” rating and set a $230.00 price objective on the stock in a report on Tuesday, March 30th. Finally, Credit Suisse Group upped their price objective on McKesson from $178.00 to $192.00 and gave the stock a “neutral” rating in a report on Wednesday, February 3rd. One investment analyst has rated the stock with a sell rating, two have given a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $193.31.

In other news, CEO Brian S. Tyler sold 5,510 shares of the company’s stock in a transaction on Tuesday, February 16th. The stock was sold at an average price of $183.38, for a total value of $1,010,423.80. Following the sale, the chief executive officer now directly owns 24,500 shares in the company, valued at $4,492,810. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Brian S. Tyler sold 5,511 shares of the company’s stock in a transaction on Thursday, April 15th. The shares were sold at an average price of $191.41, for a total value of $1,054,860.51. Following the completion of the sale, the chief executive officer now owns 24,501 shares in the company, valued at $4,689,736.41. The disclosure for this sale can be found here. 0.28% of the stock is owned by corporate insiders.

About McKesson

McKesson Corporation provides pharmaceuticals and medical supplies in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions, International, and Medical-Surgical Solutions. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar, and over-the-counter pharmaceutical drugs and other healthcare-related products.

See Also: What is the price-sales ratio?

Earnings History for McKesson (NYSE:MCK)

Receive News & Ratings for McKesson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for McKesson and related companies with MarketBeat.com's FREE daily email newsletter.

Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit